Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
  • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
  • C07D491/14—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
  • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
  • C07D513/04—Ortho-condensed systems

Definitions

• the present invention relates to novel [1,2] fused 7-heteroaryl-1,4-benzodiazepine compounds and their salts, as well as pharmaceutical preparations containing these compounds and processes for the preparation of these compounds.
• the invention has for its object to develop new [1,2] fused 1,4-benzodiazepine compounds with valuable pharmacological properties.
• the [1,2] fused 7-heteroaryl-1,4-benzodiazepine compounds according to the invention differ from the previously known 5-heteroaryl-1,4-benzodiazepines of US Pat. No. 3,403,161 and DE-A-2 314 993 in its chemical structure essentially due to the presence of a further heterocycle fused in the 1,2-position.
• the compounds of the invention differ structurally from the [1,2] fused 7-phenyl-1,4-benzodiazepines of EP-A-0 008 045 in that they contain a 7-heteroaryl group instead of the 7-phenyl group.
• substituents R 1 and R 2 in the compounds of the formula I represent or contain a lower alkyl group, this means a straight or branched alkyl group with 1-4 carbon atoms, in particular methyl or ethyl.
• these lower alkyl substituents are preferably methyl and the lower alkoxy or alkylthio substituents are preferably methoxy or methylthio.
• halogen atoms in particular fluorine, chlorine or bromine are suitable.
• the substituents R 1 and R 2 are preferably in the 9- and / or 10-position or, if they mean N0 2 or CF 3 , in the 9-position and are preferably hydrogen, methoxy, methyl, chlorine, bromine or fluorine.
• R 4 denotes an alkyl group which is optionally substituted as defined above, this preferably represents a straight-chain alkyl group with 1-5, in particular 1-3 carbon atoms.
• R 4 preferably stands for Methyl, ethyl, methoxyethyl or hydroxyethyl.
• R 5 is lower alkyl, this is straight or branched, contains 1-4 carbon atoms and is preferably methyl or ethyl.
• R 5 is in particular hydrogen, C 1 -C 4 alkyl or nitro, preferably hydrogen or methyl.
• R 5 is in particular hydrogen, lower alkyl, preferably methyl, fluorine, chlorine, bromine or also nitro.
• R 3 is a pyrrolyl group c
• R 5 is in particular hydrogen or methyl.
• the cyclization according to process a can take place under the ring closure conditions known from DE-A-2835708 for the formation of [1,2] -annulated benzodiazepine compounds.
• the 2-chloromethyl-1,4-benzodiazepine compounds of the formula but also the 3-chloro-1,5-benzodiazocin compounds of the formula III or mixtures of benzodiazepines of the formula II with corresponding benzodiazocines of the formula III can be used as starting compounds, since the benzodiazocin skeleton of the compounds of formula III is converted into the benzodiazepine skeleton under the cyclization conditions.
• Y in the compounds of the formula II and / or III is halogen, this can be chlorine, bromine, iodine, but preferably chlorine. If Y represents a substituted benzene sulfonyloxy group, it preferably represents a toluenesulfonyloxy group.
• the cyclizing reaction is expediently carried out in a solvent which is inert under the reaction conditions at temperatures between about 50 and 150.degree.
• Particularly suitable solvents for the cyclization are organic solvents, for example lower alcohols such as methanol, ethanol or isopropanol, lower ketones such as acetone, lower open or cyclic ethers such as diethyl ether, dioxane or tetrahydrofuran, pyridine, dimethyl sulfoxide or dimethylformamide, the addition of water being advantageous can be.
• an amine R 4 ⁇ NH 2 is used as the cyclizing agent, this amine can also be used as a solvent.
• N-oxide compounds of the formula Ia can also be obtained by oxidizing compounds of the formula Ib in a manner known per se to their corresponding N-oxides in accordance with process b.
• the oxidation can be carried out, for example, with organic peracids in an organic solvent which is inert under the reaction conditions, for example by the processes described in Chem. Rev. 68, 747 (1968).
• Perbenzoic acids such as 3-chloroperbenzoic acid are particularly suitable as oxidizing agents.
• Halogenated hydrocarbons such as methylene chloride are suitable as solvents.
• Compounds of the formula Ic can also be obtained by reducing the corresponding N-oxides of the formula Id in a manner known per se (see, for example, J. Org. Chem. 26, 1111 (1961)).
• a particularly suitable reducing agent is PCl 3 in an organic solvent which is inert under the reaction conditions, for example a halogenated hydrocarbon such as chloroform or methylene chloride.
• furyl compounds of the formula IV can be converted into pyrrole compounds of the formula le by reaction with an amine R e -NH 2 .
• the conversion of the furyl radical into the pyrrolyl radical can take place at temperatures between 80 and 150 ° C. under the cyclization conditions described under process a.
• Subsequent substitution in the phenyl ring of the 1,4-benzodiazepine skeleton is either in the fused-on end products of the formula I or at the stage of the cyclized intermediates of the formulas II and / or III in a manner known per se by halogen or if R 3 is not Pyrrolyl represents, the nitro group possible.
• Halogenating agents which can be used are, for example, N-chlorosuccinimide or N-bromosuccinimide.
• the usual nitration reagents can be used to introduce the nitro group, for example KNO 3 in H 2 S0 4 or copper (II) nitrate trihydrate in acetic anhydride as a gentle nitration reagent.
• an existing nitro group can also subsequently be converted into halogen in a manner known per se or can be split off completely.
• the compounds of the formula obtained by the processes according to the invention can in themselves be isolated and purified in a known manner in the form of the free bases or their acid addition salts.
• Acid addition salts can be converted into the free bases in a conventional manner and, if desired, these can be converted into pharmacologically acceptable acid addition salts in a known manner.
• a solution of a compound of the formula I in a solvent is mixed with the acid desired as the salt component.
• Organic solvents in which the corresponding salt is sparingly soluble are preferably chosen for the reaction.
• inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid
• organic acids for example organic sulfonic acids such as methane or toluenesulfonic acids or cyclohexylaminosulfonic acid
• lower aliphatic carboxylic acids which may optionally be hydroxylated or may contain a double bond
• succinic acid tartaric acid, fumaric acid, maleic acid or citric acid
• lower aromatic carboxylic acids such as benzoic acid.
• the compounds of the formula according to the invention are obtained in the form of their racemates in the synthesis.
• the protection of this invention now covers both the racemic mixtures and the optically active forms of the compounds of the formula I.
• the optically active compounds can be obtained from the racemic mixtures in a manner known per se by salt formation with suitable optically active acids, such as, for example, tartaric acid, and subsequent fractional crystallization of the salts obtained can be separated into their optically active antipodes.
• benzodiazepine compounds of the formula II and benzodiazocin compounds of the formula III used as starting substances are new. They can be produced in a manner known per se, for example by the methods described in DE-A-2 221 558, 2353187 or 2810 349.
• the compounds of the formula VII or their acid addition salts are expediently treated as described in DE-A-2 520 937 with phosphorus oxychloride at a temperature between 100 and 150 ° C., preferably at the boiling point of the reaction mixture.
• phosphorus oxychloride at a temperature between 100 and 150 ° C., preferably at the boiling point of the reaction mixture.
• R 7 ' is methoxy
• this group can be converted into the hydroxy group in a manner known per se by cleavage with hydroiodic acid, which can then be esterified in a manner known per se to give a sulfonyl ester group Y or can be converted into a halogen group Y.
• nitro groups can also be introduced into the phenyl part of the ring structure in a manner known per se at this stage.
• the compounds of the formula IIIa and IIIa can be converted into the corresponding N-oxides in a manner known per se, for example under the conditions given above for process b.
• 2-halobenzoyl compounds of the formula XII can also be used in which R 1 and R 2 and R 3 'have the above meaning and Hal is halogen, preferably chlorine or fluorine. These are firstly reacted with a propanol diamine compound of the formula XIII. where R 7 has the above meaning and Q for one into one. Amino group transferable radical, for example a protected amino group, and subsequent conversion of group Q into the free amino group in compounds of formula XIV wherein R 1 , R 2 and R 3 'have the above meaning, transferred.
• the compounds of the formula XIV can be converted into compounds of the formula II in a manner known per se by cyclization and subsequent conversion of the group R 7 into the group Y. This process is particularly suitable for the preparation of compounds of the formula II in which the phenyl ring of the benzodiazepine skeleton contains a nitro group.
• heteroaryl-substituted [1,2] fused 1,4-benzodiazepine derivatives according to the invention and their pharmacologically acceptable acid addition salts have valuable pharmacological properties and show a profile of activity which is completely new for 1,4-benzodiazepines.
• phenyl-substituted 1,4-benzodiazepine derivatives e.g. B. the known from DE-A-2835708 ulcer inhibiting compounds or known as minor tranquilizers 5-phenyl-1,4-benzodiazepin-2-ones such as diazepam or chlorodiazepoxide, characterized in that they have a pronounced neuroleptic active component, while for Typical tranquilizer effects are largely suppressed.
• the compounds according to the invention thus show strong effects in standard animal experiments which are suitable for the detection of neuroleptic effects.
• the compounds in mice typically inhibit apomorphine-induced (psychotic) climbing behavior in a manner typical of neuroleptics.
• Central sedative properties are only present in the compounds to a much lesser extent, as can be seen in standard tests, e.g. B. shows by measuring the prolongation of the hexobarbital anesthetic duration in mice.
• the neuroleptically active 1,4-benzodiazepine derivatives according to the invention have only a slight degree of sedative effect in the neuroleptically effective dose range and are distinguished by a low toxicity and a wide therapeutic range. Due to their favorable activity profile, they are suitable for use in the treatment of diseases of the schizophrenic type.
• novel activity profile of the compounds according to the invention can be seen from the results of the standard pharmacological tests on mice described below.
• the acute 7-day toxicity is determined after a single application per os to the white, fasted NMRI mouse and the LD 50 values are calculated by EDP using a probit analysis.
• mice Groups of 10 male NMRI mice each with a body weight of 18-24 g are used per test dose.
• the test substance is applied by os suspended in 2% tylose solution.
• the following table shows the inhibitory effect in% inhibition compared to the climbing behavior of a control group not treated with the test substance.
• mice Groups of 10 male mice of 22-26 g body weight per test dose are used.
• the test substance is applied by os suspended in 2% tylose solution.
• the duration of the erection reflex loss is measured in tenths of a minute.
• the extension of this duration of the reflex loss caused by the test substance is determined by a comparison with the duration of the reflex loss in control animals treated only with a test substance-free tylose solution and hexobarbital sodium.
• the table below shows the extension factor caused by the test substances.
• the compounds of the formula and their physiologically tolerable acid addition salts can be administered as pharmaceuticals together with conventional pharmaceutical auxiliaries in pharmaceutical preparations, the dosage of the species to be treated and the individual requirements being adapted.
• Parenteral formulations will generally contain less active substance than preparations for oral administration. Tablets, capsules, powders, granules, dragees, solutions, emulsions, suspensions or suppositories may be mentioned as examples of galenical forms of preparation. These galenical preparations can be prepared by methods known per se using customary pharmaceutical carriers and / or auxiliaries.
• Solid preparations can contain inorganic carriers such as talc or organic carriers such as milk sugar or starch and, if appropriate, further auxiliaries customary for tablet production, such as, for example, lubricants, for example magnesium stearate, binders or tablet detonating agents.
• Liquid preparations can be the usual diluents such as water, liquid fatty oils or paraffin and optionally other auxiliaries, eg. B. contain suspending agents such as polyoxyethylene glycol, emulsifiers and the like.
• the structures of the new compounds are confirmed by spectroscopic investigations, in particular by an exact analysis of the NMR spectra.
• Amounts of water, acetone, ethanol or the like that may be included are listed in the table for salt forms.
• 43 g of a mixture of about equal parts of the benzodiazepine and benzodiazocin isomers are obtained from the mother liquor after stripping off the solvent in vacuo and cleaning the remaining residue of aluminum oxide of activity levels II to III with methylene chloride. This mixture is refluxed in 215 ml of tetrachloroethane for 1 hour. After the solvent has been stripped off in vacuo, the reaction product is treated with aqueous sodium hydroxide solution and again chromatographically purified on aluminum oxide and then crystallized from ether. A further 34 g of the benzodiazepine compound with a melting point of 92 to 94 ° C. are obtained.
• reaction mixture is then worked up as usual and the reaction product is purified by chromatography on aluminum oxide of activity level II with methylene chloride / chloroform, the fractions containing the medium polar product being separated off and the 1,2,3,4,4a, 5-hexahydro- 9-chloro-3-methyl-7- (2-furyl) pyrazino [1,2-a] [1,4] benzodiazepine dissolved in isopropanol and converted into its salt with alcoholic hydrochloric acid. This crystallizes from isopropanol as dihydrochloride hemihydrate with 0.1 mol isopropanol, mp:> 240 ° C, yield 0.8 g.
• Tablets are produced in the following composition per tablet:
• the active ingredient, corn starch and milk sugar are thickened with the 10% gelatin solution.
• the paste is crushed and the resulting granulate is placed on a suitable plate brought and dried at 45 ° C.
• the dried granulate is passed through a comminution machine and mixed in a mixer with the following auxiliaries:

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Neurology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (3)

Family

ID=6149862

Family Applications (1)

Country Status (20)

Families Citing this family (4)

Family Cites Families (9)

• 1981
  • 1981-12-28 DE DE19813151597 patent/DE3151597A1/de not_active Withdrawn
• 1982
  • 1982-11-10 PT PT75966A patent/PT75966B/pt unknown
  • 1982-12-13 PH PH28270A patent/PH19310A/en unknown
  • 1982-12-21 AT AT82111881T patent/ATE26116T1/de not_active IP Right Cessation
  • 1982-12-21 DE DE8282111881T patent/DE3275830D1/de not_active Expired
  • 1982-12-21 EP EP82111881A patent/EP0084155B1/de not_active Expired
  • 1982-12-21 JP JP57223133A patent/JPS58118590A/ja active Pending
  • 1982-12-22 GR GR70150A patent/GR78408B/el unknown
  • 1982-12-23 NZ NZ202902A patent/NZ202902A/en unknown
  • 1982-12-24 CA CA000419548A patent/CA1194474A/en not_active Expired
  • 1982-12-24 AU AU91927/82A patent/AU555893B2/en not_active Ceased
  • 1982-12-27 IL IL67564A patent/IL67564A/xx unknown
  • 1982-12-27 NO NO824379A patent/NO158462C/no unknown
  • 1982-12-27 HU HU824167A patent/HU186207B/hu unknown
  • 1982-12-27 FI FI824479A patent/FI73684C/fi not_active IP Right Cessation
  • 1982-12-27 ES ES518573A patent/ES8308565A1/es not_active Expired
  • 1982-12-27 DK DK574582A patent/DK574582A/da not_active Application Discontinuation
  • 1982-12-27 SU SU823527852A patent/SU1331431A3/ru active
  • 1982-12-27 US US06/453,785 patent/US4508716A/en not_active Expired - Lifetime
  • 1982-12-27 DD DD82246622A patent/DD208807A5/de unknown
  • 1982-12-28 ZA ZA829526A patent/ZA829526B/xx unknown
• 1985
  • 1985-03-01 US US06/707,037 patent/US4594436A/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events